Strasbourg University Hospitals | COMBATT | Inflammatory Diseases | e-cohort

COMBATT is a national observatory of targeted therapies administered in combination for various refractory immune-mediated inflammatory diseases.

Its main objective is to evaluate the safety/tolerance of targeted treatments (in mono- or combination therapy) administered to patients with refractory autoimmune or autoinflammatory diseases (outside of clinical trials).

This observatory follows, retrospectively and in real time, patients with systemic autoimmune diseases who initiate a targeted therapy (either alone or in combination) starting from January 1, 2019.

Role of Alsinova: Optimization of the e-CRFs for data collection, implementation of the data collection platform, and hosting of the platform for the entire duration of the study.